Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
Background: Daclizumab is a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor, used for the treatment of relapsing-remitting multiple sclerosis with a large spectrum of cutaneous adverse reactions. Case presentation: We present the case of a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2019-03-01
|
| Series: | Journal of Interdisciplinary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/jim-2018-0038 |